AI-powered biotech startups are leveraging automation, data, and gene editing to address labor shortages in drug discovery and treatment of rare diseases. Despite advanced tools in biotech, numerous rare diseases remain untreated due to a lack of skilled personnel. At Web Summit Qatar, executives from Insilico Medicine and GenEditBio highlighted the potential of AI to tackle longstanding industry challenges.
Insilico’s AI platform integrates biological, chemical, and clinical data to propose hypotheses on disease targets and candidate molecules. By automating tasks that previously demanded extensive human resources, the company aims to accelerate the identification of potential therapies and repurposing of existing drugs, significantly cutting costs and time.
For instance, Insilico successfully repurposed existing drugs to potentially treat ALS, a rare neurological disorder, showcasing the versatility and impact of AI in addressing critical healthcare challenges.
The integration of AI in drug discovery not only streamlines the identification of therapeutic candidates but also plays a pivotal role in addressing labor shortages and accelerating the development of treatments for neglected rare diseases.
Source: TechCrunch